Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
LOS ANGELES, March 18, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (Nasdaq:STML) concerning possible violations of federal securities laws. Investors who purchased or otherwise acquired Stemline shares between January 19, 2017 and February 1, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 4, 2017 lead plaintiff deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
On February 2, 2017, Bloomberg confirmed that a patient undergoing a clinical trial of Stemline’s cancer drug SL-401 died from a severe side effect, the third death related to SL-401 toxicity.
When this information was revealed to the public, the value of Stemline stock fell sharply, causing investors severe harm.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
